How Longevity Research Can Lead to Therapies for Alzheimer's Disease: The Rapamycin Story

Overview

Journal Exp Gerontol

Specialty Geriatrics

Date 2014 Dec 8

PMID 25481271

Citations 67

Authors

Arlan Richardson

Veronica Galvan

Ai-Ling Lin

Salvatore Oddo

Affiliations

Soon will be listed here.

Abstract

The discovery that rapamycin increases lifespan in mice and restores/delays many aging phenotypes has led to the speculation that rapamycin has 'anti-aging' properties. The major question discussed in this review is whether a manipulation that has anti-aging properties can alter the onset and/or progression of Alzheimer's disease, a disease in which age is the major risk factor. Rapamycin has been shown to prevent (and possibly restore in some cases) the deficit in memory observed in the mouse model of Alzheimer's disease (AD-Tg) as well as reduce Aβ and tau aggregation, restore cerebral blood flow and vascularization, and reduce microglia activation. All of these parameters are widely recognized as symptoms central to the development of AD. Furthermore, rapamycin has also been shown to improve memory and reduce anxiety and depression in several other mouse models that show cognitive deficits as well as in 'normal' mice. The current research shows the feasibility of using pharmacological agents that increase lifespan, such as those identified by the National Institute on Aging Intervention Testing Program, to treat Alzheimer's disease.

Citing Articles

Mikhail 'Misha' Blagosklonny's enduring legacy in geroscience: the hyperfunction theory and the therapeutic potential of rapamycin.

Barzilai D Aging (Albany NY). 2025; 17(1):1-15.

PMID: 39808121 PMC: 11810056. DOI: 10.18632/aging.206189.

mTOR inhibition enhances synaptic and mitochondrial function in Alzheimer's disease in an APOE genotype-dependent manner.

Sanganahalli B, Mihailovic J, Vekaria H, Coman D, Yackzan A, Flemister A J Cereb Blood Flow Metab. 2024; 44(10):1745-1758.

PMID: 38879800 PMC: 11494852. DOI: 10.1177/0271678X241261942.

Evaluating the effect of rapamycin treatment in Alzheimer's disease and aging using in vivo imaging: the ERAP phase IIa clinical study protocol.

Svensson J, Bolin M, Thor D, Williams P, Brautaset R, Carlsson M BMC Neurol. 2024; 24(1):111.

PMID: 38575854 PMC: 10993488. DOI: 10.1186/s12883-024-03596-1.

Targeting Cellular Senescence in Aging and Age-Related Diseases: Challenges, Considerations, and the Emerging Role of Senolytic and Senomorphic Therapies.

Zheng L, He S, Wang H, Li J, Liu Y, Liu S Aging Dis. 2024; 15(6):2554-2594.

PMID: 38421832 PMC: 11567261. DOI: 10.14336/AD.2024.0206.

Rapamycin Responds to Alzheimer's Disease: A Potential Translational Therapy.

Hou S, Zhang S, Li Y, Xu S Clin Interv Aging. 2023; 18:1629-1639.

PMID: 37810956 PMC: 10557994. DOI: 10.2147/CIA.S429440.

References

Hsia A, Masliah E, McConlogue L, Yu G, Tatsuno G, Hu K . Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci U S A. 1999; 96(6):3228-33. PMC: 15924. DOI: 10.1073/pnas.96.6.3228. View

Casadio A, Martin K, Giustetto M, Zhu H, Chen M, Bartsch D . A transient, neuron-wide form of CREB-mediated long-term facilitation can be stabilized at specific synapses by local protein synthesis. Cell. 1999; 99(2):221-37. DOI: 10.1016/s0092-8674(00)81653-0. View

Nagata K, Kondoh Y, Atchison R, Sato M, Satoh Y, Watahiki Y . Vascular and metabolic reserve in Alzheimer's disease. Neurobiol Aging. 2000; 21(2):301-7. DOI: 10.1016/s0197-4580(00)00130-5. View

Vezina C, Kudelski A, Sehgal S . Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo). 1975; 28(10):721-6. DOI: 10.7164/antibiotics.28.721. View

Mucke L, Yu G, McConlogue L, Rockenstein E, Abraham C, Masliah E . Astroglial expression of human alpha(1)-antichymotrypsin enhances alzheimer-like pathology in amyloid protein precursor transgenic mice. Am J Pathol. 2000; 157(6):2003-10. PMC: 1885780. DOI: 10.1016/s0002-9440(10)64839-0. View

Tang S, Reis G, Kang H, Gingras A, Sonenberg N, Schuman E . A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus. Proc Natl Acad Sci U S A. 2002; 99(1):467-72. PMC: 117583. DOI: 10.1073/pnas.012605299. View

Camardo J . The Rapamune era of immunosuppression 2003: the journey from the laboratory to clinical transplantation. Transplant Proc. 2003; 35(3 Suppl):18S-24S. DOI: 10.1016/s0041-1345(03)00356-7. View

Oddo S, Caccamo A, Shepherd J, Murphy M, Golde T, Kayed R . Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003; 39(3):409-21. DOI: 10.1016/s0896-6273(03)00434-3. View

Tischmeyer W, Schicknick H, Kraus M, Seidenbecher C, Staak S, Scheich H . Rapamycin-sensitive signalling in long-term consolidation of auditory cortex-dependent memory. Eur J Neurosci. 2003; 18(4):942-50. DOI: 10.1046/j.1460-9568.2003.02820.x. View

10.

Dubois S, Shou W, Haneline L, Fleischer S, Waldmann T, Muller J . Distinct pathways involving the FK506-binding proteins 12 and 12.6 underlie IL-2-versus IL-15-mediated proliferation of T cells. Proc Natl Acad Sci U S A. 2003; 100(24):14169-74. PMC: 283564. DOI: 10.1073/pnas.2335979100. View

11.

Vellai T, Takacs-Vellai K, Zhang Y, Kovacs A, Orosz L, Muller F . Genetics: influence of TOR kinase on lifespan in C. elegans. Nature. 2003; 426(6967):620. DOI: 10.1038/426620a. View

12.

Ravikumar B, Vacher C, Berger Z, Davies J, Luo S, Oroz L . Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet. 2004; 36(6):585-95. DOI: 10.1038/ng1362. View

13.

Kapahi P, Zid B, Harper T, Koslover D, Sapin V, Benzer S . Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway. Curr Biol. 2004; 14(10):885-90. PMC: 2754830. DOI: 10.1016/j.cub.2004.03.059. View

14.

Bonegio R, Fuhro R, Wang Z, Valeri C, Andry C, Salant D . Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol. 2005; 16(7):2063-72. DOI: 10.1681/ASN.2004030180. View

15.

Pakala R, Stabile E, Jang G, Clavijo L, Waksman R . Rapamycin attenuates atherosclerotic plaque progression in apolipoprotein E knockout mice: inhibitory effect on monocyte chemotaxis. J Cardiovasc Pharmacol. 2005; 46(4):481-6. DOI: 10.1097/01.fjc.0000177985.14305.15. View

16.

Kaeberlein M, Powers 3rd R, Steffen K, Westman E, Hu D, Dang N . Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients. Science. 2005; 310(5751):1193-6. DOI: 10.1126/science.1115535. View

17.

Sarbassov D, Ali S, Sengupta S, Sheen J, Hsu P, Bagley A . Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006; 22(2):159-68. DOI: 10.1016/j.molcel.2006.03.029. View

18.

Hansen M, Taubert S, Crawford D, Libina N, Lee S, Kenyon C . Lifespan extension by conditions that inhibit translation in Caenorhabditis elegans. Aging Cell. 2007; 6(1):95-110. DOI: 10.1111/j.1474-9726.2006.00267.x. View

19.

Erlich S, Alexandrovich A, Shohami E, Pinkas-Kramarski R . Rapamycin is a neuroprotective treatment for traumatic brain injury. Neurobiol Dis. 2007; 26(1):86-93. DOI: 10.1016/j.nbd.2006.12.003. View

20.

Jia K, Levine B . Autophagy is required for dietary restriction-mediated life span extension in C. elegans. Autophagy. 2007; 3(6):597-9. DOI: 10.4161/auto.4989. View